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Abstract Arrhythmogenic cardiomyopathy (AC), also
known as arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C), is a hereditary disease
characterised by ventricular arrhythmias, right ventricular
and/or left ventricular dysfunction, and fibrofatty replacement
of cardiomyocytes. Patients with AC typically present be-
tween the second and the fourth decade of life with ventricular
tachycardias. However, sudden cardiac death (SCD) may be
the first manifestation, often at young age in the concealed
stage of disease. AC is diagnosed by a set of clinically appli-
cable criteria defined by an international Task Force. The
current Task Force Criteria are the essential standard for a
correct diagnosis in individuals suspected of AC. The genetic
substrate for AC is predominantly identified in genes
encoding desmosomal proteins. In a minority of patients a
non-desmosomal mutation predisposes to the phenotype. Risk
stratification in AC is imperfect at present. Genotype-
phenotype correlation analysis may provide more insight into
risk profiles of index patients and family members. In addition
to symptomatic treatment, prevention of SCD is the most
important therapeutic goal in AC. Therapeutic options in
symptomatic patients include antiarrhythmic drugs, catheter
ablation, and ICD implantation. Furthermore, patients with
AC and also all pathogenic mutation carriers should be ad-
vised against practising competitive and endurance sports.
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Introduction
Arrhythmogenic right ventricular (RV) dysplasia/
cardiomyopathy (ARVD/C) is histopathologically
characterised by progressive fibrofatty replacement of
cardiomyocytes, primarily in the right ventricle [1–3].
However, histopathologically and functionally the left ventri-
cle is affected in many cases and both ventricles are similarly
affected by desmosomal and gap junctional protein redistri-
bution [4, 5]. Because of these observations, at present ar-
rhythmogenic cardiomyopathy (AC) is the preferred terminol-
ogy [6]. AC can be defined as a structural myocardial disease
preceded by ventricular arrhythmias. Typical ARVD/C with
predominant RV abnormalities can be considered a large and
important subcategory of AC. Clinical diagnosis is made
according to international consensus-based Task Force
Criteria [7, 8].
The first series of ARVD/C patients was published in 1982
[1]. It was described as a developmental disease of the RV
musculature, hence the terminology ‘dysplasia’. In the past
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25 years, increased insight into the development of the disease
as well as the discovery of pathogenic gene mutations in-
volved led to the current understanding that AC is a geneti-
cally determined cardiomyopathy. The molecular genetic sub-
strate for the disease is mainly acknowledged in genes
encoding desmosomal adhesion proteins in the intercalated
disk [9–14].
This review provides an overview of AC, from phenotypic
and genetic features of the disease, to diagnosis, risk stratifi-
cation and treatment options.
Epidemiology
Estimations of the prevalence of AC in the general population
vary from 1:1000 to 1:5000 [15, 16]. The real prevalence of
AC, however, is unknown and is presumably higher due to
many non-diagnosed and misdiagnosed cases. In one study,
features of AC were detected at post-mortem evaluation in as
many as 20 % of sudden deaths occurring in people under
35 years of age [17]. In nearly half of them, no prior symptoms
had been reported. Furthermore, in the study by Tabib et al.
[18], 26 % of forensic autopsy cases following exercise-
related sudden cardiac death (SCD) under the age of 30 years
revealed AC.
From the genetic point of view, both men and women
should be equally affected. However, men are more frequently
diagnosed with AC than women. In a large multicentre study,
57 % of affected individuals were male. As many women as
men show at least some signs of disease, but women less
frequently fulfil criteria to meet the diagnosis [19]. It is spec-
ulated that (sports) activity or hormonal factors may play a
role in this difference in severity of disease expression [20].
Familial disease, with AC diagnosis in at least one other
family member besides the index patient, has been demon-
strated in more than one-third of AC cases [21, 22].
Presentation
Patients with AC typically present between the second and the
fourth decade of life with palpitations, lightheadedness, or
syncope due to ventricular ectopy or (monomorphic) ventric-
ular tachycardia (VT) with left bundle branch block (LBBB)
morphology, thus originating from the right ventricle (Fig. 1).
However, SCDmay be the first clinical manifestation, often at
young age in the concealed stage of disease. In a study by
Quarta et al. [22], SCD was the presenting symptom in 50 %
of index patients, with SCD occurring in 31 % at young age,
i.e. between 14 and 20 years. A presentation with (aborted)
SCD occurred less often in other studies [19, 23–25]. In the
Dutch AC cohort, 2/149 (1.3 %) index patients presented with
SCD and 8 % (12/149) with aborted SCD [21].
AC can present in four clinical stages which do not neces-
sarily proceed from one into the other: 1) concealed stage
without or with minimal structural disease, although SCD
may occur, 2) overt stage with structural alterations of primar-
ily the right ventricle, and episodes of monomorphic VT, 3)
overt stage with obvious structural biventricular involvement,
and 4) the end-stage of the disease with heart failure [1, 26,
27]. Recently, left ventricular (LV) dominant and primarily
biventricular variants have also been described, in analogy
with the AC concept [4, 28].
Diagnosis
Accurate AC diagnosis is critical due to lifelong implications,
not only for the index patient but also for family members.
Diagnosis has been facilitated by a set of clinically applicable
criteria. These criteria, originally formulated for ARVD/C,
were defined by an international Task Force based on consen-
sus in 1994 and were revised in 2010 [7, 8]. In the revised
Task Force Criteria (TFC) a minor criterion for (additional)
LV involvement, inverted Twaves in left precordial leads V4-
6, was incorporated. The current TFC are the essential stan-
dard for a correct diagnosis in individuals suspected of AC. In
addition, its universal acceptance contributes importantly to
unambiguous interpretation of clinical studies and facilitates
comparison of results. The TFC include six different catego-
ries: 1) global and/or regional dysfunction and structural RV
alterations, 2) tissue characterisation, 3) depolarisation abnor-
malities, 4) repolarisation abnormalities, 5) arrhythmias, and
6) family history and genetics. Within these groups, diagnostic
criteria are categorised as major or minor according to their
disease specificity. A diagnosis of AC is made with the fulfil-
ment of two major, one major and two minor, or with four
minor TFC. From each different category, only one criterion
can be counted for diagnosis, even when multiple criteria in
one group are present. Table 1 provides an overview of the
TFC defined in 2010. Figure 2 demonstrates typical
repolarisation abnormalities in AC patients. Several studies
suggested that this new set of criteria improved the diagnostic
yield, with equal specificity [22, 29, 30]. Despite these efforts,
AC diagnosis in the concealed stage of disease with subse-
quent risk for SCD still poses a great challenge for physicians.
Specific evaluations are recommended in all patients
suspected of AC: detailed history and family history, physical
examination, 12-lead ECG (while off medications), signal
averaged ECG, 24-hour Holter monitoring, maximal exercise
testing, two-dimensional echocardiography with quantitative
wall motion analysis, and more detailed imaging by cardiac
magnetic resonance imaging (MRI) with delayed enhance-
ment analysis. Invasive tests are also useful for diagnostic
purposes: RV and LV cineangiography, electrophysiological
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testing, and endomyocardial biopsies for histopathological
and immunohistochemical analysis [5, 31].
Differential diagnosis
Early and occasionally late stages of AC may show similari-
ties with a few other diseases. In particular, differentiation
from idiopathic VT originating from the RV outflow tract
(RVOT) can be challenging. However, idiopathic RVOT VT
is a benign non-familial condition, in which the ECG shows
no depolarisation or repolarisation abnormalities and no RV
structural changes can be detected. Furthermore, VT episodes
have a single morphology (LBBB morphology with inferior
axis) and are based on abnormal automaticity or triggered
activity, whereas reentry is the prevalent arrhythmia mecha-
nism in AC [32, 33]. It is important to differentiate idiopathic
RVOT VT from AC with regard to screening of family mem-
bers, prognosis, and outcome of catheter ablation.
Another disease mimicking AC is cardiac sarcoidosis [34].
Clinical symptoms of cardiac involvement are present in about
5 % of all patients with sarcoidosis. In a study by Vasaiwala
et al. [35] a remarkably high incidence (15 %) of cardiac
sarcoidosis was found in patients with suspected AC.
Presence of extracardiac sarcoidosis, mediastinal lymphade-
nopathy, septal conduction abnormalities, and septal scar on
cardiac imaging may be indicative of cardiac sarcoidosis
rather than AC as disease aetiology [36]. Histopathological
findings from endomyocardial biopsies can differentiate be-
tween the two entities. Nonetheless, cardiac sarcoidosis may
mimic AC even on the molecular level. In a recent study by
Asimaki et al. [37] a markedly reduced immunoreactive signal
in the intercalated disk of the desmosomal protein plakoglobin
was observed in AC as well as in cardiac sarcoidosis patients.
Myocarditis might also be considered in the differential
diagnosis. In general, endomyocardial biopsy is required to
distinguish myocarditis from AC. In analogy with cardiac
sarcoidosis, giant cell myocarditis may be indistinguishable
from AC using immunohistochemical analysis. In contrast,
viral myocarditis does not result in plakoglobin redistribution
from the intercalated disk. Differential profiles of cytokines
are implicated to underlie this difference in disruption of
desmosomal proteins [37].
AC may also mimic dilated cardiomyopathy (DCM), es-
pecially in the more advanced stages of disease. However,
patients with DCM usually present with heart failure rather
than arrhythmias. Thus, patients with sustained VTor SCD as
the initial symptom of a supposed DCM, should also be
screened for AC.
Finally, there are a number of other rare differential diag-
noses to consider: Brugada syndrome with similar electrocar-
diographic or RV arrhythmias, congenital abnormalities such
as Uhl’s disease, Ebstein’s anomaly, and atrial-septal defects,
RV infarction, and possibly pulmonary hypertension [27].
Molecular genetic background of AC
In 2000, the seminal discovery ofmutations in the plakoglobin
(JUP) gene as the basis of Naxos disease, an autosomal
recessive cardio-cutaneous syndrome with AC, directed the
search for the genetic substrate to other genes encoding
Fig. 1 12-lead ECG of a ventricular tachycardia (VT) in an arrhythmo-
genic cardiomyopathy (AC) index patient with a pathogenic and a most
likely pathogenic plakophilin-2 mutation (c.397C>T p.Gln133* and
c.2615C>T p.Thr872Ile). The VT has a left bundle branch block
morphology, with inferior axis. The QRS complex is predominantly
negative in lead aVL and most positive in lead II, suggesting an origin
from the right ventricular outflow tract area in the right ventricle
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Table 1 Overview of the current Task Force Criteria for arrhythmogenic cardiomyopathy (AC) diagnosis
I. Global or regional dysfunction and structural alterations Major:
- By 2D echo
○ Regional RVakinesia, dyskinesia, or aneurysm
○ And 1 of the following (end diastole): PLAX RVOT ≥32 mm (correct for
body size [PLAX/BSA] ≥19 mm/m2), PSAX ≥36 mm (correct for body size
[PSAX/BSA] ≥21 mm/m2, or fractional area change <33 %
- By MRI
○ Regional RVakinesia or dyskinesia or dyssynchronous RV contraction
○ And 1 of the following: ratio of RVEDV to BSA ≥110 mL/m2
(male) or ≥100 mL/m2 (female), or RVejection fraction ≤40 %
- By RV cine-angiography
○ Regional RVakinesia, dyskinesia, or aneurysm
Minor:
- By 2D echo
○ Regional RVakinesia or dyskinesia
○ And 1 of the following (end diastole): PLAX RVOT ≥29 to <32 mm
(correct for body size [PLAX/BSA] ≥16 to <19 mm/m2), PSAX ≥32 to <36 mm
(correct for body size [PSAX/BSA] ≥18 to <21 mm/m2, or fractional area change
≤33 to ≤40 %
- By MRI
○ Regional RVakinesia or dyskinesia or dyssynchronous RV contraction
○ And 1 of the following: ratio of RVEDV to BSA ≥100 mL/m2 to <110 mL/m2
(male) or ≥90 mL/m2 to <100 mL/m2 (female), or RVejection
fraction >40 to ≤45 %
II. Tissue characterisation of wall Major:
- Residual myocytes <60 % by morphometric analysis (or <50 % if estimated),
with fibrous replacement of the RV free wall myocardium in ≥1 sample, with
or without fatty replacement of tissue on endomyocardial biopsy
Minor:
- Residual myocytes 60–75 % by morphometric analysis (or 50–65 % if estimated),
with fibrous replacement of the RV free wall myocardium in ≥1 sample, with
or without fatty replacement of tissue on endomyocardial biopsy
III. Repolarisation abnormalities Major:
- Inverted T waves in right precordial leads (V1, V2, V3) or beyond in
individuals >14 years of age
Minor:
- Inverted T waves in leads V1 and V2 in individuals >14 years of age or in V4, V5, V6
- Inverted T waves in leads V1, V2, V3 and V4 in individuals >14 years of age
in the presence of complete right bundle branch block
IV. Depolarisation/conduction abnormalities Major:
- Epsilon wave (reproducible low-amplitude signals after the end of the QRS
complex to onset of the T wave) in right precordial leads (V1, V2, V3)
Minor:
- Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS
duration of ≥110 ms on the standard ECG
- Filtered QRS duration (fQRS) ≥114 ms
- Duration of terminal QRS <40 uV (low-amplitude signal duration) ≥38 ms
- Root-mean-square voltage of terminal 40 ms ≤20 uV
- Terminal activation duration ≥55 ms measured from the nadir of the S wave
to the end of all depolarisation deflections, including R′, in V1, V2 or V3 in
the absence of complete right bundle branch block
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Table 1 (continued)
V. Arrhythmias Major:
- Nonsustained or sustained ventricular tachycardia of left bundle branch
morphology with superior axis (negative or indeterminate QRS in leads II, III,
and aVF and positive in lead aVL)
Minor:
- Nonsustained or sustained ventricular tachycardia of RVOT configuration,
left bundle branch block morphology with inferior axis (positive QRS in II, III
and aVF and negative in aVL) or unknown axis
- >500 ventricular extrasystoles per 24h (Holter)
VI. Family history Major:
- AC confirmed in a first-degree relative who meets current TFC
- AC confirmed pathologically at autopsy or surgery in a first-degree relative
- Identification of a pathogenic mutation categorised as associated
or probably associated with AC in the patient under evaluation
Minor:
- History of AC in a first-degree relative in whom it is not possible or practical
to determine whether the family member meets current TFC
- Premature sudden death (<35years of age) due to suspected AC
in a first-degree relative
- AC confirmed pathologically or by current TFC in second-degree relative
The TFC, originally formulated for arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), include six different categories.Within these
groups, diagnostic criteria are categorised as major or minor according to their disease specificity. A diagnosis of AC is made with the fulfilment of two
major, one major and two minor, or with four minor TFC. From each different category, only one criterion can be counted for diagnosis, even when
multiple criteria in one group are present
BSA body surface area, first-degree family member parent, sibling or child; PLAX parasternal long-axis view, PSAX parasternal short-axis view, RVEDV
right ventricular end-diastolic volume, RVOT right ventricular outflow tract, SAECG signal averaged ECG, second-degree family member uncle/aunt,
niece/nephew, grandparent
Fig. 2 12-lead ECG (during atenolol 25 mg once daily) of the same
index patient as in Figure 1. The ECG shows sinus rhythm, horizontal
axis, and typical negative Twaves in the right precordial leads V1-3. The
terminal activation duration (from the nadir of the S wave to the end of all
depolarisation deflections) in leads V1-3 is normal (≤55 ms)
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desmosomal proteins [9]. This candidate gene approach iden-
tified mutations first in the desmoplakin (DSP) gene, and
thereafter in the plakophilin-2 (PKP2), desmoglein-2
(DSG2), and desmocollin-2 (DSC2) genes [10, 11, 13, 14].
In the Netherlands, as in most European countries, and in
North America, mutations are predominantly found in the
PKP2 gene [21, 22, 25, 38, 39]. PKP2 mutations are found
in 52 % of Dutch AC index patients and even in 90 % of
familial cases [21]. This high yield is partly explained by the
occurrence of founder mutations in the Netherlands.
Haplotype analysis suggested a founder effect of four different
PKP2 mutations [38, 40]. On the other hand, there are geo-
graphical differences in the prevalence of AC-related gene
mutations [13, 41].
Desmosomes are protein complexes located in the interca-
lated disk and are amongst others important for mechanical
integrity of adjacent cardiomyocytes (Fig. 3) [42].
Desmosomal dysfunction due to a gene mutation may give
rise to loss of mechanical cell-cell adhesion, and leads to
down-regulation and/or altered distribution of other interca-
lated disk proteins, i.e. gap junction proteins (Connexin43)
and sodium channels (Nav1.5) [43–45]. These alterations give
rise to electrical cell-cell uncoupling and slow conduction,
respectively, thereby providing a substrate for early activation
delay resulting in ventricular tachyarrhythmia, a hallmark of
AC [5, 12, 46, 47]. Presumably, at a later stage myocyte loss
and fibrofatty replacement will have a major impact on tissue
architecture, giving rise to zig-zag conduction pathways and
load mismatch, further contributing to enhanced activation
delay [32, 48].
Although the function of the desmosome and other com-
ponents of the intercalated disk becomes increasingly clear,
the exact mechanism by which a gene mutation results in the
disease remains to be elucidated. Furthermore, not every
subject with a mutation and thus a predisposition for AC
develops signs and symptoms of the disease. Additional ge-
netic factors, e.g. compound or digenic heterozygosity (carry-
ing more than one mutation in one or more genes), or envi-
ronmental factors such as exercise, may explain differences in
severity of disease evolution within mutation carriers [49, 50].
In a minority of patients a non-desmosomal gene mutation is
associated with the AC phenotype. Mutations in the non-
desmosomal transforming growth factor β3 (TGFβ3), trans-
membrane protein 43 (TMEM43), desmin (DES), titin (TTN),
lamin A/C (LMNA), αT-catenin (CTNNA3), and phospholam-
ban (PLN) genes have been related to index patients and/or
families with AC [51–57]. Of note, the PLN founder mutation
c.40_42delAGA has been identified in 13 % of AC index
patients in the Netherlands. AC patients with the PLNmutation
often have low-voltage electrocardiograms, negative Twaves in
the left precordial leads V4-6, and additional LV involvement
(Fig. 4) [58, 59]. To facilitate interpretation of genetic data, a
large web-based database of genes and mutations underlying
AC has been created (www.arvcdatabase.info). This database
currently contains information on nearly 900 variants [60].
Not all forms of AC are genetically proven. These cases
may be explained by mutations in yet unknown genes, by the
contribution of genetic variants of unknown significance in
the known genes, or epigenetic phenomena. The evaluation of
a family history of AC, suggesting a still unknown genetic
factor, is crucial in patients without identifiable genetic pre-
disposition. Alternatively, these cases may be due to environ-
mental factors, for example exercise. Exercise was a trigger
and accelerator of the AC phenotype in a mouse model with
JUP haploinsufficiency [61]. Very recently, the effect of exer-
cise on AC disease expression was corroborated in humans.
Of 87 pathogenic AC mutation carriers, 56 were endurance
athletes. Endurance athletes were more likely to have symp-
toms at young age, fulfil the 2010 TFC, and had lower
survival free from VT, ventricular fibrillation (VF), and heart
failure. A reversible effect of reduction of sports activities,
being a significant decrease in risk for VTor VF, was observed
in those individuals who exercised themost (top quartile) [20].
Risk stratification
Risk stratification in AC is imperfect at present. The annual
mortality rates reported vary from 0.08–3.6% [23, 24, 62, 63].
Retrospective analysis of clinical and pathological studies
identified several risk factors for sudden death or appropriate
ICD therapy, such as previously aborted SCD, syncope,
young age, severe RV dysfunction, and LV involvement.
Patients without VT had the best prognosis [23, 63].
Presence of sustained and non-sustained VT on Holter mon-
itoring or during exercise testing, and sustained VT/VF during
Fig. 3 Schematic representation of the molecular organisation of cardiac
desmosomes. The plasma membrane (PM) spanning proteins
desmocollin-2 (DSC2) and desmoglein-2 (DSG2) interact in the extracel-
lular space at the dense midline (DM). At the cytoplasmic side, they
interact with plakoglobin (PG) and plakophilin-2 (PKP2) at the outer
dense plaque (ODP). The PKP2 and PG also interact with desmoplakin
(DSP). At the inner dense plaque (IDP), the C-terminus of DSP anchors
the intermediate filament desmin (DES). (Source: Reprint with permis-
sion from: Van Tintelen et al. Curr Opin Cardiol. 2007;22:185–92)
Neth Heart J (2014) 22:316–325 321
electrophysiological study were significant predictors of ICD
therapy in a multivariate analysis in 84 patients treated with
ICDs for primary prevention (appropriate ICD therapy in
48 %, of which 19 % for VF/ventricular flutter episodes)
[64]. More recently, Te Riele et al. [65] showed that sustained
arrhythmias in AC patients presenting alive seem to coincide
with structural abnormalities and that patients with solely
electrical abnormalities have a lower arrhythmic risk, impli-
cating a role for RV structural abnormalities in risk
stratification.
Molecular genetic analysis is also of importance in risk
stratification in AC since cascade screening allows early de-
tection of presymptomatic disease, identification of individ-
uals at risk, and genetic counselling for this sudden death-
predisposing disease. However, incorporating genetic results
in AC risk stratification is hampered by incomplete penetrance
and an extremely variable clinical expression. Mutation car-
riers may present with SCD but can also remain without signs
and symptoms of the disease into old age. Therefore, genetic
screening results should be viewed as probabilistic and as part
of the overall clinical assessment.
Genotype-phenotype correlation analysis can provide more
insight into risk profiles of index patients and family mem-
bers. In contrast to index patients, mutation-positive family
members have a better prognosis, with signs and symptoms of
AC present in 50 % of relatives in their fifth decades of life
[22]. Furthermore, family members with more than one ge-
netic variant had a significant fivefold increase in risk of
disease expression, suggesting gene-gene interactions and
gene-dose effects. A genotype-phenotype correlation study
by our group showed that compared with relatives of index
patients without mutations, mutation carrying family mem-
bers had 1) a sixfold higher risk of AC diagnosis, 2) a mark-
edly enhanced risk for ventricular arrhythmias, and 3) earlier
onset of AC signs and symptoms [21].
Clinical management
In addition to symptomatic treatment, prevention of SCD is
the most important therapeutic goal in AC. As there have been
no randomised trials of AC treatment modalities, screening
regimens, or medications, most recommendations are based
on clinical expertise, results of retrospective registry-based
studies, and studies on model systems.
Evidence suggests that, in the absence of sustained and
non-sustained VT and/or high number of ventricular prema-
ture complexes (>1000VPC/24 h), asymptomatic patients and
healthy mutation carriers do not require treatment with an ICD
for primary prevention [64]. These individuals should under-
go regular cardiac evaluations (every 1–2 years) including 12-
lead ECG, 24-h Holter monitoring, echocardiography, and
exercise testing for timely identification of unfavourable signs
necessitating ICD implantation.
However, in all patients diagnosed with or having signs or
symptoms of AC as well as asymptomatic mutation carriers,
specific lifestyle advice is recommended. Sports participation
has been shown to increase the risk of SCD fivefold in AC
patients [66]. Furthermore, excessive mechanical stress, such
as during competitive sports activity and training, may aggra-
vate underlying myocardial abnormalities and accelerate dis-
ease progression [20, 61]. Therefore, patients with AC, and in
Fig. 4 12-lead ECG (while off medications) of a phospholamban foun-
der mutation carrier (c.40_42delAGA, p.Arg14del). The ECG shows
sinus rhythmwith right axis deviation, low voltages (<0.5 mVin standard
leads), and characteristic negative T waves in left precordial leads from
V3-6. The terminal activation duration (from the nadir of the S wave to
the end of all depolarisation deflections) is 60 ms and therefore prolonged
in lead V1 (vertical black lines)
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our opinion also all pathogenic mutation carriers, should be
advised against practising competitive and endurance sports.
Therapeutic options in symptomatic patients with AC in-
clude antiarrhythmic drugs, catheter ablation, and ICD im-
plantation. However, at present ICD implantation is the only
proven lifesaving therapeutic modality for fast VT/VF. In
patients who have presented with stable sustained VT but also
patients and family members with non-sustained VT or >500
VPC on 24-h Holter monitoring, medication may be consid-
ered to reduce arrhythmias and symptoms. This pharmacolog-
ical reduction may be critically important in combination with
ICD therapy to reduce shock delivery. Since ventricular ar-
rhythmias and cardiac arrest occur frequently during or after
physical exercise or may be triggered by catecholamines, non-
class III antiadrenergic beta-blockers are recommended. In the
absence of adequate antiarrhythmic response, sotalol in an
appropriate dose is the drug of first choice. Alternatively,
amiodarone and flecainide have been reported to be useful
[67]. Efficacy of drug treatment has to be evaluated by serial
Holter monitoring and/or exercise testing.
Catheter ablation is an alternative in patients who are
refractory to drug treatment and have frequent VT episodes
(with a predominantly single morphology) [68]. Of note, the
role of this therapy in AC patients is to improve quality of life
by decreasing the frequency of episodes of sustained VT,
symptomatic non-sustained VT, and ventricular ectopy.
Accordingly, in a recent study by Philips et al. [69] the overall
freedom from VT of 175 ablation procedures in 87 AC pa-
tients was 47 %, 21 %, and 15 %, at 1, 5, and 10 years,
respectively, over a mean follow-up of 88.3±66 months.
The outcomes of VT ablation are improved with a combined
endocardial and epicardial approach, incorporating a
substrate-based strategy [69, 70].
Although antiarrhythmic drugs and catheter ablation may
reduce VT burden, there is no proof from prospective trials
that these therapies will also prevent SCD. Implantation of an
ICD is indicated in AC patients who are intolerant to antiar-
rhythmic drug therapy and who are at serious risk for SCD, in
patients with aborted cardiac arrest, intolerable fast VT and
those with risk factors as mentioned above.
AC in the Netherlands
In the Netherlands, a national collaboration of all University
Medical Centers participating in ICIN has resulted in a large
dataset with genetic and phenotypic characteristics of AC
index patients and family members [21]. Since the prevalence
of AC is relatively low, collaboration is essential for adequate
studies and thereby improvement of insight into AC. This
collaboration has expedited studies on AC-related genes,
founder mutations, new diagnostic AC parameters, and clin-
ical outcome of index patients and family members.
Continuation of inclusion of more individuals, longer
follow-up, and implementation of results of next generation
DNA sequencing are needed to optimise further risk
stratification.
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